JP7695887B2 - 抗il-33抗体を含有する安定化製剤 - Google Patents

抗il-33抗体を含有する安定化製剤 Download PDF

Info

Publication number
JP7695887B2
JP7695887B2 JP2021556435A JP2021556435A JP7695887B2 JP 7695887 B2 JP7695887 B2 JP 7695887B2 JP 2021556435 A JP2021556435 A JP 2021556435A JP 2021556435 A JP2021556435 A JP 2021556435A JP 7695887 B2 JP7695887 B2 JP 7695887B2
Authority
JP
Japan
Prior art keywords
pharmaceutical formulation
antibody
liquid pharmaceutical
stable liquid
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021556435A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022526292A5 (cg-RX-API-DMAC7.html
JP2022526292A (ja
Inventor
チンヤン・フー
ディンヂィァン・リウ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2022526292A publication Critical patent/JP2022526292A/ja
Publication of JP2022526292A5 publication Critical patent/JP2022526292A5/ja
Priority to JP2025094518A priority Critical patent/JP2025131756A/ja
Application granted granted Critical
Publication of JP7695887B2 publication Critical patent/JP7695887B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
    • A61M5/178—Syringes
    • A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
    • A61M5/3205—Apparatus for removing or disposing of used needles or syringes, e.g. containers; Means for protection against accidental injuries from used needles
    • A61M5/321—Means for protection against accidental injuries by used needles
    • A61M5/3243—Means for protection against accidental injuries by used needles being axially-extensible, e.g. protective sleeves coaxially slidable on the syringe barrel
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
    • A61M5/178—Syringes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Environmental & Geological Engineering (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
JP2021556435A 2019-03-21 2020-03-20 抗il-33抗体を含有する安定化製剤 Active JP7695887B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025094518A JP2025131756A (ja) 2019-03-21 2025-06-06 抗il-33抗体を含有する安定化製剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962821661P 2019-03-21 2019-03-21
US62/821,661 2019-03-21
PCT/US2020/023795 WO2020191270A1 (en) 2019-03-21 2020-03-20 Stabilized formulations containing anti-il-33 antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025094518A Division JP2025131756A (ja) 2019-03-21 2025-06-06 抗il-33抗体を含有する安定化製剤

Publications (3)

Publication Number Publication Date
JP2022526292A JP2022526292A (ja) 2022-05-24
JP2022526292A5 JP2022526292A5 (cg-RX-API-DMAC7.html) 2023-03-24
JP7695887B2 true JP7695887B2 (ja) 2025-06-19

Family

ID=70228884

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021556435A Active JP7695887B2 (ja) 2019-03-21 2020-03-20 抗il-33抗体を含有する安定化製剤
JP2025094518A Pending JP2025131756A (ja) 2019-03-21 2025-06-06 抗il-33抗体を含有する安定化製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025094518A Pending JP2025131756A (ja) 2019-03-21 2025-06-06 抗il-33抗体を含有する安定化製剤

Country Status (19)

Country Link
US (2) US11596690B2 (cg-RX-API-DMAC7.html)
EP (1) EP3941522A1 (cg-RX-API-DMAC7.html)
JP (2) JP7695887B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210141592A (cg-RX-API-DMAC7.html)
CN (3) CN113573733B (cg-RX-API-DMAC7.html)
AU (1) AU2020241882A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021018727A2 (cg-RX-API-DMAC7.html)
CA (1) CA3133995A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021002440A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021011648A2 (cg-RX-API-DMAC7.html)
EA (1) EA202192568A1 (cg-RX-API-DMAC7.html)
IL (2) IL317899A (cg-RX-API-DMAC7.html)
MA (1) MA55362A (cg-RX-API-DMAC7.html)
MX (1) MX2021011137A (cg-RX-API-DMAC7.html)
PH (1) PH12021552092A1 (cg-RX-API-DMAC7.html)
SA (1) SA521430229B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202109822XA (cg-RX-API-DMAC7.html)
TW (2) TWI861073B (cg-RX-API-DMAC7.html)
WO (1) WO2020191270A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20212185A1 (es) 2019-02-18 2021-11-11 Lilly Co Eli Formulacion de anticuerpos terapeuticos
WO2021228760A1 (en) * 2020-05-11 2021-11-18 Medimmune Limited Formulations of anti-il-33 antibodies
CN113603775B (zh) 2021-09-03 2022-05-20 江苏荃信生物医药股份有限公司 抗人白介素-33单克隆抗体及其应用
WO2023077685A1 (zh) * 2021-11-04 2023-05-11 江苏荃信生物医药股份有限公司 包含抗人白介素-33单克隆抗体的浓缩溶液的制备方法及液体制剂
CN113842457B (zh) * 2021-11-04 2022-05-20 江苏荃信生物医药股份有限公司 包含抗人白介素-33单克隆抗体的液体制剂
WO2026067832A1 (zh) * 2024-09-30 2026-04-02 深圳市小分子新药创新中心有限公司 抗il-33单域抗体及其衍生物

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009523039A (ja) 2006-01-10 2009-06-18 サルバス テクノロジー リミテッド 安全針
JP2013543505A (ja) 2010-10-06 2013-12-05 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗インターロイキン−4受容体(il−4r)抗体を含有する安定化製剤
JP2015528465A (ja) 2012-08-31 2015-09-28 バイエル・ヘルスケア・エルエルシーBayer HealthCareLLC 抗プロラクチン受容体抗体製剤
WO2018102597A1 (en) 2016-12-01 2018-06-07 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory conditions
WO2018169348A1 (ko) 2017-03-16 2018-09-20 주식회사 엘지화학 항-tnf 알파 항체의 액상 제제

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0747045B2 (ja) 1986-10-15 1995-05-24 株式会社大協精工 積層した注射器用滑栓
JP3100727B2 (ja) 1992-01-23 2000-10-23 株式会社大協精工 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品
JP3172057B2 (ja) 1995-04-05 2001-06-04 株式会社大協精工 ラミネートゴム栓
JP3512349B2 (ja) 1999-01-29 2004-03-29 株式会社大協精工 柱状ゴム要素の成形型
GB2361704C (en) * 2000-03-03 2006-08-02 Cambridge Antibody Tech Human antibodies against eotaxin and their use
JP2002209975A (ja) 2001-01-19 2002-07-30 Daikyo Seiko Ltd 医薬バイアル用ラミネートゴム栓
NZ549040A (en) 2004-02-17 2009-07-31 Schering Corp Use for interleukin-33 (IL33) and the IL-33 receptor complex
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US8119771B2 (en) 2007-04-26 2012-02-21 The Provost, Fellow and Scholars of the College of the Holy and Undivided Trinity of Queen Elizabeth, Near Dublin Products for altering IL-33 activity and methods thereof
JP2010527936A (ja) 2007-05-18 2010-08-19 メディミューン,エルエルシー 炎症性疾患におけるil−33
EP2475388B1 (en) 2009-09-10 2017-11-08 Merck Sharp & Dohme Corp. Use of il-33 antagonists to treat fibrotic disease
WO2013059524A2 (en) * 2011-10-18 2013-04-25 Emory University Antibodies directed against influenza
CN118286417A (zh) * 2012-09-07 2024-07-05 瑞泽恩制药公司 以il-4r拮抗剂治疗特应性皮炎的方法
JO3532B1 (ar) 2013-03-13 2020-07-05 Regeneron Pharma الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
JP6858182B2 (ja) * 2015-10-06 2021-04-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. インターロイキン33(il−33)媒介疾患に関するバイオマーカーおよびその使用
EP3966227A1 (en) * 2019-05-07 2022-03-16 Voyager Therapeutics, Inc. Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
CN112851814B (zh) * 2020-03-17 2023-07-07 西安宇繁生物科技有限责任公司 一种靶向bcma的全人源单链抗体及其制备方法与应用
EP4255451A4 (en) * 2020-12-03 2025-01-01 The Board Of Regents Of The University Of Texas System Methods for identifying lilrb-blocking antibodies
TW202237639A (zh) * 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 鳥苷酸環化酶c(gcc)抗原結合劑之組成物及其使用方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009523039A (ja) 2006-01-10 2009-06-18 サルバス テクノロジー リミテッド 安全針
JP2013543505A (ja) 2010-10-06 2013-12-05 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗インターロイキン−4受容体(il−4r)抗体を含有する安定化製剤
JP2015528465A (ja) 2012-08-31 2015-09-28 バイエル・ヘルスケア・エルエルシーBayer HealthCareLLC 抗プロラクチン受容体抗体製剤
WO2018102597A1 (en) 2016-12-01 2018-06-07 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory conditions
WO2018169348A1 (ko) 2017-03-16 2018-09-20 주식회사 엘지화학 항-tnf 알파 항체의 액상 제제

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Pharm. Res., 2012.10, Vol.30, pp.641-654
免疫学イラストレイテッド 第5版, 株式会社南江堂, 2000, pp.71-82
日本畜産学会報, 1990, Vol.61, No.7, pp.655-660

Also Published As

Publication number Publication date
US20200297845A1 (en) 2020-09-24
IL286024A (en) 2021-10-31
KR20210141592A (ko) 2021-11-23
WO2020191270A1 (en) 2020-09-24
EP3941522A1 (en) 2022-01-26
SG11202109822XA (en) 2021-10-28
IL286024B1 (en) 2025-01-01
PH12021552092A1 (en) 2022-05-30
CA3133995A1 (en) 2020-09-24
BR112021018727A2 (pt) 2022-02-15
IL317899A (en) 2025-02-01
MX2021011137A (es) 2021-10-22
CO2021011648A2 (es) 2021-09-30
CN119700966A (zh) 2025-03-28
CN113573733B (zh) 2024-12-31
AU2020241882A1 (en) 2021-10-14
JP2022526292A (ja) 2022-05-24
TWI861073B (zh) 2024-11-11
SA521430229B1 (ar) 2024-01-23
TW202519263A (zh) 2025-05-16
US11596690B2 (en) 2023-03-07
CN113573733A (zh) 2021-10-29
EA202192568A1 (ru) 2021-12-03
US20230346929A1 (en) 2023-11-02
CN119700965A (zh) 2025-03-28
MA55362A (fr) 2022-01-26
IL286024B2 (en) 2025-05-01
JP2025131756A (ja) 2025-09-09
CL2021002440A1 (es) 2022-04-22
TW202102260A (zh) 2021-01-16

Similar Documents

Publication Publication Date Title
US12077593B2 (en) Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodies
US20230346929A1 (en) Stabilized Formulations Containing Anti-IL-33 Antibodies
BR112013008366B1 (pt) Formulações farmacêuticas líquidas estáveis contendo anticorpos anti-receptor de interleucina-4 humana alfa, e recipiente contendo as referidas formulações
WO2023215267A1 (en) Anti-interleukin-4 receptor (il-4r) antibody formulations
KR20220113417A (ko) 항-CD20 x 항-CD3 이중 특이적 항체를 함유한 안정화 제제
EA045976B1 (ru) Стабилизированные составы, содержащие антитела к il-33
HK40083910A (en) Stabilized formulations containing anti-interleukin-6 receptor (il-6r) antibodies
OA16466A (en) Stabilized formulations containing antiinterleukin-6 receptor (IL-6R) antibodies.
EA042167B1 (ru) Стабилизированные композиции, содержащие антитела к рецептору интерлейкина-4 (il-4r)
EA047546B1 (ru) Стабилизированные составы, содержащие антитела анти-pcsk9

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230315

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230315

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231215

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231219

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240312

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240517

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240619

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240903

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250203

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250513

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250609

R150 Certificate of patent or registration of utility model

Ref document number: 7695887

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150